Special issue dedicated in memory of Dr. Edward H. Ahrens, Jr.

Cardiovascular drug reviews Pub Date : 2002-01-01
Edward H Ahrens
{"title":"Special issue dedicated in memory of Dr. Edward H. Ahrens, Jr.","authors":"Edward H Ahrens","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This special issue of the \"Cardiovascular Drug Reviews\" is dedicated in memory of Dr. Edward H. Ahrens, Jr., who died on Dec. 9th, 2000 at the Princeton Medical Center in New Jersey at the age of 85. Dr. Ahrens was the Director of the Lipid Metabolism Laboratory at the Rockefeller University. Dr. Alexander Scriabine conceived the idea for the issue at the special memorial symposium held at the Rockefeller University on Feb. 05, 2002 under the auspices of The New York Lipid and Vascular Biology Research Club. Dr. Ahrens was the first president of the club. He started this club with Drs. Howard Eder and DeWitt Goodman. Dr. Eder thought that it would be a fitting attribute to honor one of the founding fathers of the club by hosting a memorial symposium. I, as the President of the club for that academic year, had no hesitation in accepting the proposal. This year will be the 40th anniversary of the club and its continued success provides a glimpse of the fine legacy left behind by Dr. Ahrens. Dr. Ahrens also played a pivotal role in the establishment of the Journal of Lipid Research. This is the 43rd year of the journal and in this commemorative issue we are reproducing a review he wrote for the 25th anniversary of the journal. I was never personally acquainted with Dr. Ahrens. However, I am honored that I got this opportunity to pay tribute to a great scientist whose work has contributed immensely to the progress of lipid research. He was a person who touched many lives and still continues to do so. My involvement in the remembrance of Dr. Ahrens shows that science not only impacts your contemporaries but also generations that follow you. Scientific research is a journey where you can leave your trails behind and be remembered for your work long after your departure from this world. Dr. Ahrens contributed immensely to the understanding of cholesterol metabolism. In the early stages of his career he showed that phospholipids solubilize fat in the blood. Now we know that a monolayer of phospholipids surrounds the neutral lipid core of cholesterol esters and triglycerides in lipoproteins. This monolayer contains proteins, called apolipoproteins, which play a major role in lipoprotein catabolism. Lipoproteins are the major vehicles that transport triglycerides and cholesterol in the plasma. He also described a new form of primary biliary cirrhosis characterized by the presence of xanthomas and hyperlipidemia with normal translucent plasma. Subsequently, his group at the Rockefeller Institute developed methods for the separation of lipids using silicic acid columns, isolated highly unsaturated long chain fish oil fatty acids using gas-liquid chromatography, standardized techniques to study sterol metabolism, and introduced the concept of using beta-sitosterolemia as an internal marker for cholesterol balance studies. These studies revealed that individuals show a reproducible response to a given regimen when studied over time. In contrast, different individuals may respond differently to the same regimen. Throughout his career, Dr. Ahrens championed metabolic studies in humans and has passionately argued for the continuation of such investigations. Dr. Ahrens also left behind trails of \"graduates.\" Several of them are currently prominent scientists in their own fields. In this issue, Drs. Davignon and Samuel share their feelings for him in the form of \"Remembrance\" and \"Curriculum Vitae.\" Dr. Salen has submitted a preview of his research progress towards the understanding of sitosterolemia. Dr. Hudgins and associates have acknowledged the efforts of Dr. Ahrens in binding LDL apheresis technique to the United States of America and have previewed the use of this procedure in the treatment of hypercholesterolemic patients. The contributions of these and other graduates will keep his legacy alive for a long time to come. We are truly grateful for this opportunity to pay homage to such a distinguished scientist.</p>","PeriodicalId":9490,"journal":{"name":"Cardiovascular drug reviews","volume":"20 4","pages":"237-343"},"PeriodicalIF":0.0000,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular drug reviews","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This special issue of the "Cardiovascular Drug Reviews" is dedicated in memory of Dr. Edward H. Ahrens, Jr., who died on Dec. 9th, 2000 at the Princeton Medical Center in New Jersey at the age of 85. Dr. Ahrens was the Director of the Lipid Metabolism Laboratory at the Rockefeller University. Dr. Alexander Scriabine conceived the idea for the issue at the special memorial symposium held at the Rockefeller University on Feb. 05, 2002 under the auspices of The New York Lipid and Vascular Biology Research Club. Dr. Ahrens was the first president of the club. He started this club with Drs. Howard Eder and DeWitt Goodman. Dr. Eder thought that it would be a fitting attribute to honor one of the founding fathers of the club by hosting a memorial symposium. I, as the President of the club for that academic year, had no hesitation in accepting the proposal. This year will be the 40th anniversary of the club and its continued success provides a glimpse of the fine legacy left behind by Dr. Ahrens. Dr. Ahrens also played a pivotal role in the establishment of the Journal of Lipid Research. This is the 43rd year of the journal and in this commemorative issue we are reproducing a review he wrote for the 25th anniversary of the journal. I was never personally acquainted with Dr. Ahrens. However, I am honored that I got this opportunity to pay tribute to a great scientist whose work has contributed immensely to the progress of lipid research. He was a person who touched many lives and still continues to do so. My involvement in the remembrance of Dr. Ahrens shows that science not only impacts your contemporaries but also generations that follow you. Scientific research is a journey where you can leave your trails behind and be remembered for your work long after your departure from this world. Dr. Ahrens contributed immensely to the understanding of cholesterol metabolism. In the early stages of his career he showed that phospholipids solubilize fat in the blood. Now we know that a monolayer of phospholipids surrounds the neutral lipid core of cholesterol esters and triglycerides in lipoproteins. This monolayer contains proteins, called apolipoproteins, which play a major role in lipoprotein catabolism. Lipoproteins are the major vehicles that transport triglycerides and cholesterol in the plasma. He also described a new form of primary biliary cirrhosis characterized by the presence of xanthomas and hyperlipidemia with normal translucent plasma. Subsequently, his group at the Rockefeller Institute developed methods for the separation of lipids using silicic acid columns, isolated highly unsaturated long chain fish oil fatty acids using gas-liquid chromatography, standardized techniques to study sterol metabolism, and introduced the concept of using beta-sitosterolemia as an internal marker for cholesterol balance studies. These studies revealed that individuals show a reproducible response to a given regimen when studied over time. In contrast, different individuals may respond differently to the same regimen. Throughout his career, Dr. Ahrens championed metabolic studies in humans and has passionately argued for the continuation of such investigations. Dr. Ahrens also left behind trails of "graduates." Several of them are currently prominent scientists in their own fields. In this issue, Drs. Davignon and Samuel share their feelings for him in the form of "Remembrance" and "Curriculum Vitae." Dr. Salen has submitted a preview of his research progress towards the understanding of sitosterolemia. Dr. Hudgins and associates have acknowledged the efforts of Dr. Ahrens in binding LDL apheresis technique to the United States of America and have previewed the use of this procedure in the treatment of hypercholesterolemic patients. The contributions of these and other graduates will keep his legacy alive for a long time to come. We are truly grateful for this opportunity to pay homage to such a distinguished scientist.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纪念小爱德华·h·阿伦斯博士的特刊。
这期《心血管药物评论》特刊是为了纪念爱德华·h·阿伦斯博士,他于2000年12月9日在新泽西州普林斯顿医学中心去世,享年85岁。她是洛克菲勒大学脂质代谢实验室的主任。2002年2月5日,在纽约脂质和血管生物学研究俱乐部的赞助下,亚历山大·斯克里亚宾博士在洛克菲勒大学举行的特别纪念研讨会上提出了这个问题的想法。阿伦斯博士是该俱乐部的第一任主席。他和dr。霍华德·埃德和德威特·古德曼。埃德尔博士认为通过举办一个纪念讨论会来纪念俱乐部的创始人之一是很合适的。作为那个学年的俱乐部主席,我毫不犹豫地接受了这个提议。今年将是扶轮社成立四十周年,扶轮社的持续成功让我们得以一窥阿伦斯博士留下的优良遗产。阿伦斯博士还在《脂质研究杂志》的建立中发挥了关键作用。今年是该杂志创刊的第43年,在这期纪念刊中,我们复制了他为该杂志创刊25周年而写的一篇评论。我本人从未与阿伦斯医生有过私交。然而,我很荣幸有这个机会向一位伟大的科学家致敬,他的工作对脂质研究的进展做出了巨大的贡献。他是一个感动了许多人的人,而且还在继续这样做。我参与纪念艾伦斯博士的活动表明,科学不仅影响你的同时代人,也影响你的后代。科学研究是一段旅程,在你离开这个世界很久之后,你可以留下你的痕迹,并记住你的工作。阿伦斯博士对了解胆固醇代谢作出了巨大贡献。在他职业生涯的早期阶段,他证明了磷脂可以溶解血液中的脂肪。现在我们知道,在脂蛋白中胆固醇酯和甘油三酯的中性脂质核心周围包裹着一层磷脂。这一单分子层含有载脂蛋白,它在脂蛋白分解代谢中起主要作用。脂蛋白是血浆中运输甘油三酯和胆固醇的主要载体。他还描述了一种新的原发性胆汁性肝硬化,其特征是存在黄疸和高脂血症,伴有正常的半透明血浆。随后,他在洛克菲勒研究所的团队开发了使用硅酸柱分离脂质的方法,使用气液色谱法分离高度不饱和的长链鱼油脂肪酸,标准化技术研究甾醇代谢,并引入了使用β -谷甾醇血症作为胆固醇平衡研究的内部标记物的概念。这些研究表明,随着时间的推移,个体对给定的方案表现出可重复的反应。相反,不同的人对同一种疗法的反应可能不同。在他的整个职业生涯中,阿伦斯博士一直倡导人类代谢研究,并热情地主张继续进行此类研究。阿伦斯博士也留下了一批“毕业生”。他们中的一些人目前是各自领域的杰出科学家。在本期中,dr。达维侬和塞缪尔以“回忆”和“简历”的形式分享了他们对他的感情。Salen博士已经提交了他对谷固醇血症的研究进展的预览。Hudgins博士及其同事对Ahrens博士在美国结合低密度脂蛋白分离技术方面所做的努力表示认可,并预览了该技术在治疗高胆固醇血症患者中的应用。这些和其他毕业生的贡献将使他的遗产在未来很长一段时间内保持活力。我们非常感谢有这个机会向这样一位杰出的科学家致敬。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abbott-57219[SCH-40054]: A Novel Nasal Decongestant DPI 201-106 Bopindolol: Pharmacological Basis and Clinical Implications Cardiovascular effects of raloxifene hydrochloride. Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1